Literature DB >> 15105837

Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.

T M Ganten1, T L Haas, J Sykora, H Stahl, M R Sprick, S C Fas, A Krueger, M A Weigand, A Grosse-Wilde, W Stremmel, P H Krammer, H Walczak.   

Abstract

Tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) exhibits potent antitumour activity upon systemic administration in mice without showing the deleterious side effects observed with other apoptosis-inducing members of the TNF family such as TNF and CD95L. TRAIL may, thus, have great potential in the treatment of human cancer. However, about 60% of tumour cell lines are not sensitive to TRAIL. To evaluate the mechanisms of tumour resistance to TRAIL, we investigated hepatocellular carcinoma (HCC) cell lines that exhibit differential sensitivity to TRAIL. Pretreatment with chemotherapeutic drugs, for example, 5-fluorouracil (5-FU), rendered the TRAIL-resistant HCC cell lines sensitive to TRAIL-induced apoptosis. Analysis of the TRAIL death-inducing signalling complex (DISC) revealed upregulation of TRAIL-R2. Caspase-8 recruitment to and its activation at the DISC were substantially increased after 5-FU sensitisation, while FADD recruitment remained essentially unchanged. 5-FU pretreatment downregulated cellular FLICE-inhibitory protein (cFLIP) and specific cFLIP downregulation by small interfering RNA was sufficient to sensitise TRAIL-resistant HCC cell lines for TRAIL-induced apoptosis. Thus, a potential mechanism for TRAIL sensitisation by 5-FU is the increased effectiveness of caspase-8 recruitment to and activation at the DISC facilitated by the downregulation of cFLIP and the consequent shift in the ratio of caspase-8 to cFLIP at the DISC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15105837     DOI: 10.1038/sj.cdd.4401437

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  72 in total

1.  Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level.

Authors:  A Morizot; D Mérino; N Lalaoui; G Jacquemin; V Granci; E Iessi; D Lanneau; F Bouyer; E Solary; B Chauffert; P Saas; C Garrido; O Micheau
Journal:  Cell Death Differ       Date:  2010-11-12       Impact factor: 15.828

Review 2.  Following the TRAIL from hepatitis C virus and alcohol to fatty liver.

Authors:  S C Afford; D H Adams
Journal:  Gut       Date:  2005-11       Impact factor: 23.059

3.  TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies.

Authors:  Bruno-Christian Koehler; Toni Urbanik; Binje Vick; Regina-Johanna Boger; Steffen Heeger; Peter-R Galle; Marcus Schuchmann; Henning Schulze-Bergkamen
Journal:  World J Gastroenterol       Date:  2009-12-21       Impact factor: 5.742

4.  Non-invasive fluorescence imaging of cell death in fresh human colon epithelia treated with 5-Fluorouracil, CPT-11 and/or TRAIL.

Authors:  Niklas Finnberg; Seok-Hyun Kim; Emma E Furth; Jue Judy Liu; Pierre Russo; David A Piccoli; Adda Grimberg; Wafik S El-Deiry
Journal:  Cancer Biol Ther       Date:  2005-09-18       Impact factor: 4.742

5.  BAX-dependent mitochondrial pathway mediates the crosstalk between ferroptosis and apoptosis.

Authors:  Young-Sun Lee; Kalishwaralal Kalimuthu; Yong Seok Park; Xu Luo; M Haroon A Choudry; David L Bartlett; Yong J Lee
Journal:  Apoptosis       Date:  2020-10       Impact factor: 4.677

6.  DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.

Authors:  Rui Yu; Stella Maris Albarenque; Robbert H Cool; Wim J Quax; Andrea Mohr; Ralf M Zwacka
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

7.  Upregulated TRIM32 correlates with enhanced cell proliferation and poor prognosis in hepatocellular carcinoma.

Authors:  Xiaopeng Cui; Zhipeng Lin; Yuyan Chen; Xiaofei Mao; Wenkai Ni; Jinxia Liu; Huiling Zhou; Xiaohang Shan; Lingling Chen; Jiale Lv; Zhongyi Shen; Chengwei Duan; Baoying Hu; Runzhou Ni
Journal:  Mol Cell Biochem       Date:  2016-08-30       Impact factor: 3.396

8.  Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib.

Authors:  D Lecis; C Drago; L Manzoni; P Seneci; C Scolastico; E Mastrangelo; M Bolognesi; A Anichini; H Kashkar; H Walczak; D Delia
Journal:  Br J Cancer       Date:  2010-05-11       Impact factor: 7.640

Review 9.  Caspase control: protagonists of cancer cell apoptosis.

Authors:  M V Fiandalo; N Kyprianou
Journal:  Exp Oncol       Date:  2012-10

10.  Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis.

Authors:  Ronald Koschny; Heidrun Holland; Jaromir Sykora; Hande Erdal; Wolfgang Krupp; Manfred Bauer; Ulrike Bockmuehl; Peter Ahnert; Jürgen Meixensberger; Wolfgang Stremmel; Henning Walczak; Tom M Ganten
Journal:  J Neurooncol       Date:  2009-09-20       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.